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We have recently discovered that cancer cells take up extracellular citrate through
plasma membrane citrate transporter (pmCiC) and advantageously use citrate for their
metabolism. Citrate uptake can be blocked with gluconate and this results in decreased
tumor growth and altered metabolic characteristics of tumor tissue. Interestingly,
gluconate, considered to be physiologically neutral, is incidentally used in medicine as a
cation carrier, but not as a therapeutically active substance. In this review we discuss the
results of our recent research with available literature and suggest that gluconate may be
useful in the treatment of cancer.
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INTRODUCTION
Despite intense basic and clinical cancer research, progress in controlling and curing malignancies
remains slow. Surgery, chemotherapy and radiotherapy are often palliative especially for advanced
cancer, and can have severe side effects. Emerging immunotherapies are showing promise, but
much work still needs to be done to prove their efficacy against a wide variety of tumors, and tumors
with little immunogenicity will likely not respond well to these therapies.
Intense research efforts are directed toward identifying novel anti-cancer drugs and to discover
known substances with potential antineoplastic effects that have been used for indications other
than cancer (1). This latter approach has the advantage that new discoveries with approved
substances can be moved more quickly to clinical application. In the present review we chose to
concentrate on gluconate as an interesting candidate molecule that is often used as a “carrier”
for putative antineoplastic substances, therefore disguising its own potential anti-cancer activities.
We raise the possibility that activities thought to be attributed entirely to the putative active
antineoplastic substance, may at least in part be due to the activity of gluconate. Based on our own
studies and the available literature we propose that gluconate should be studied as an anti-cancer
drug alone or in combination with chemotherapy. This idea is particularly attractive since gluconate
use as an excipient is approved by the FDA and is considered to have little in the way of any side
effects. Herein, we also present an interpretation of the existing data explaining why gluconate
could also be useful in the diagnosis of cancer.
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GLUCONATE
Gluconate is a glucose derivative, existing as a salt of gluconic
acid known to chelate divalent metals; gluconic acid is found
naturally in fruits, honey and wine. As a membrane impermeant
anion, gluconate is often used in biomedical research as Cl−
substitute (2, 3). In medicine, gluconate is used most commonly
as a biologically neutral carrier of Zn2+, Ca2+, Cu2+, Fe2+, and
K+ to treat relevant ion deficiencies. Furthermore, gluconate
is also combined with other drugs such as chlorohexindine,
which is used as an antiseptic in surgery (4) or dental care (5);
sodium antimony (stibogluconate) is used to treat leishmaniasis
(6). Importantly, however, while gluconate is exploited for these
purposes in medicine, it is not considered to be physiologically
active and has not been studied for its own therapeutic effects.
MECHANISM OF GLUCONATE
SUPPRESSION OF CANCER GROWTH
How can the hypothesis of gluconate’s anticancer effects be
rationalized scientifically? Although citrate is considered a
central substrate in cancer cell metabolism, its source remains
debatable. Interestingly, several recent metabolomic studies
indicate a correlation between metastatic disease and decreased
level of citrate in blood, tissues and urine of cancer patients (7–
11), to which an increased need of the cancer for citrate could
contribute. It is also possible that under these pathophysiological
conditions decreased citrate could be accounted for by increased
liver metabolism, especially regarding fatty acid synthesis (12).
Since hepatocytes express Na+-dependent citrate transporter
(NaCT), increased citrate uptake from blood could additionally
be associated with increased metabolic liver function (13). We
have recently put forward a hypothesis in which cancer cells take
up extracellular citrate and use it to support their metabolism,
especially fatty acid synthesis (14). Our work shows that cancer
cells take up extracellular citrate through the plasma membrane
citrate transporter (pmCiC) belonging to the SLC25 family and
that expression of this transporter is mainly restricted to cancer
cells (14). We have also shown that cancer cell metabolism
benefits from extracellular citrate uptake by decreasing its
mitochondrial activity and in consequence ROS synthesis,
thereby reducing cancer cell requirements for extracellular
glucose supply. Importantly, we have discovered that gluconate
is a competitive and irreversible blocker of the pmCiC, thus
decreasing the uptake of extracellular citrate by cancer cells,
and inhibiting human tumor growth in immunodeficient mice
(summarized in Figure 1). This observation together with largely
cancer cell-specific expression of pmCiC provides a mechanistic
explanation for why gluconate could be partially responsible
for the increased anti-cancer effects observed when used with
other therapeutics, like Zn2+ and Ca+2. For instance, therapeutic
remissions observed when using Zn2+ gluconate for ocular
melanoma and acute lymphocytic leukemia could actually be
related to the presence of gluconate (15, 16), as will be detailed
later in this review. Of course some of the observed effects
are likely due to ions carried by gluconate, such as increased
immune activity associated with Zn2+, or protection against
neuropathy known to be due to Ca2+. Furthermore, from a
diagnostic standpoint, our research finding that gluconate binds
to the pmCiC provides an explanation for why 99mTc gluconate
(technetium-99m, used in medicine as a radioactive tracer due
to its short half-life), is guided specifically to malignant cancer
entities. The following part of this article presents available data
related to the use of gluconate in cancer treatment and diagnosis.
We include an interpretation of the potential gluconate effects
based on our own studies.
STIBOGLUCONATE IN CANCER
IMMUNOTHERAPY
Stibogluconate (sodium antimony gluconate, sodium
stibugluconate, pentostam, stibium Sb gluconate) is an
anti-parasitic drug that incorporates gluconate into the
drug substance. It belongs to the anti-leishmaniasis group
of drugs called pentavalent-(V)-antimony compounds in
which antimony (Sb) is used (17–19). It has been suggested
that stibogluconate acts through immune system stimulation,
mainly by increasing the amount of peripheral IFN-γ+ T cells
(20). Importantly, this increased immune response has been
observed in mice (21), as well as in humans (22). Because of
its stimulating effect on the immune system, the drug was
considered a good candidate for cancer research. Indeed,
application of stibogluconate in vivo in mice with implanted
human tumor cells consistently resulted in either significant
tumor growth inhibition or total tumor regression. Human renal
cell carcinoma growth was significantly inhibited in mice using
stibogluconate (21). Similar results were obtained when mice
bearing human melanoma cells were treated with this substance
(23). Interestingly, other pentavalent antimony compounds,
not incorporating gluconate, including triphenylantimony-
(V)-polyamines and monomeric species, showed limited
effects on cancer cells [reviewed by (24)]. Furthermore,
trivalent-(III)-antimony, not associated with gluconate, has
not shown promising anti-tumor effects (applied in the form
of organometallic compounds such as diphenylantimony(III)
thiolates). Application of these compounds against leukemia in
mice did not give a substantial survival advantage and showed
high dosage-dependent toxicity (25).
Why therefore are some antimony forms effective against
cancer (stibogluconate), and others are not? Possible
explanations include differences in transport mechanism of
alternative forms of antimony, which are still not well-defined.
While transport of antimony-(III) from the extra- to intracellular
space is thought to occur through aquaglyceroporins and hexose
transporters, proteins involved in the uptake of antimony-(V)
have not been identified [reviewed by Maciaszczyk-Dziubinska
et al. (26)]. What is known is that antimony-(V) is taken up by
cells at a lower rate than antimony-(III) and is metabolically
reduced within the cell to antimony-(III) through the action
of glutathione; this process occurs before cytotoxic effects are
apparent (27, 28). Interestingly, experiments in vitro (29) show
that cancer cells that are resistant to antimony-(III) action, are
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FIGURE 1 | Schematic drawing showing the effects of extracellular citrate on cancer cell metabolism (blue arrows). Extracellular citrate is taken up by the cells through
the plasma membrane citrate transporter (pmCiC). Its uptake reduces the need of mitochondrial-derived citrate (transported from mitochondria through mCiC) and is
mainly used in cytoplasm to support fatty acid and amino acid synthesis. When the pmCiC is blocked with gluconate (brown arrows), extracellular citrate cannot get
through the plasma membrane of cancer cells resulting in increased use of glycolysis to support mitochondrial citrate synthesis. CPTI and II (Carnitine
palmitoyltransferase I and II) depict AcetylCoA transport mechanism. The thickness of lines reflects the intensity of pathway use.
sensitive to stibogluconate [antimony-(V) treatment]. Together,
these reports indicating that cells resistant to antimony-(III)
are not resistant to stibogluconate [antimony-(V)] lead us to
the hypothesis that gluconate could be an, if not the, active
anti-cancer substance in this scenario.
OTHER STUDIES AND TRIALS INVOLVING
GLUCONATE
PD-1
PD-1 (programmed death 1) receptors on T lymphocytes provide
an immune checkpoint that functions to prevent over-activation
of the immune system to antigenic challenges. Importantly,
malignant tumors often evolve to express programmed death-
ligand 1 (PD-L1), which is the ligand for PD-1 that suppresses
T cell activation (30) and thereby prevents the immune system
from destroying cancer cells. Targeting PD-1 has indeed proved
to be an effective target in cancer therapy to boost antitumor
immunity (30–33). Clinical trials using anti-PD-1 antibody
have produced positive results in a subgroup of patients with
certain types of cancer (34–36). Unfortunately, this treatment is
often accompanied by severe side-effects, including autoimmune
reactions (37, 38). In an attempt to decrease these adverse
effects, a self-degradable microneedle patch was developed to
deliver the anti-PD1 antibody directly to melanoma lesions.
To facilitate gradual release of the anti-PD-1-antibody and to
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control release into the cancer site, a system was invented to
encapsulate antibody in pH-sensitive dextran nanoparticles. To
decrease pH locally, glucose oxidase converting blood glucose
to gluconic acid was encapsulated together with the anti-PD-
1 antibody in dextran sensitive nanoparticles. Locally increased
levels of gluconic acid in blood (decreasing pH) were expected
to induce destruction of dextran nanoparticles allowing for the
release of the antibody. Interestingly, addition of this enzyme
significantly increased survival of mice with B16F10 melanoma
cells and decreased tumor growth as compared to patches with
antibody, but no glucose oxidase (39). We raise the possibility
that the additional anticancer effect was at least in part due to
the locally increased gluconate level, thus blocking extracellular
citrate uptake by cancer cells.
Zn2+ Gluconate
Encouraging results with Zn2+ gluconate used as an adjuvant
therapy to standard chemotherapy have been obtained when
treating children with acute lymphocytic leukemia, with Zn2+
being applied to stimulate the immune system. Administration
of Zn2+ gluconate significantly improved the effects of
chemotherapy. While 30 days of chemotherapy application
usually leads to bone marrow blast reduction to 3–5% when
applied together with Zn2+ gluconate, it resulted in undetectable
numbers of blasts. In this case Zn2+ gluconate was administered
2x per day from the start of chemotherapy until the end of 3
years of maintenance therapy (16). This treatment resulted in
a complete bone marrow remission and normal hematopoietic
function in all 13 children. Interestingly, application of 6-
mercaptopurin accompanied by Zn2+ sulfate used to treat acute
lymphoblastic leukemia did not produce this effect, but notably
the application was over a significantly shorter time period
(40). Nonetheless, this result is in keeping with our hypothesis
regarding the potential anti-cancer effect of gluconate.
Very promising results were also obtained from the phase 1
trial of an IRX-2 (mmunostimulatory drug comprising a variety
of cytokines derived from lymphocytes) regimen in patients
with squamous cell carcinoma of the head and neck (41). Out
of 8 patients only 2 showed progressive tumors after 21 days
of treatment. Interestingly, IRX-2 treatment in this trial was
accompanied by a daily intake of Zn2+ gluconate. Zn2+ was
added because of its known effects on the immune system,
reflected by Zn2+ deficiencies associated with decreased numbers
and activity of different types of immune cells (42). Intriguingly,
zinc deficiency has been correlated with several types of cancer
(43). The fact that gluconate was used as part of the Zn2+
formulation in the IRX-2 study presents the possibility that
pmCiC blockade could also have contributed to the anti-cancer
effects that were observed.
It is also important to discuss one particular case report
describing successful long-term treatment of a liver metastasis
from ocular melanoma (15). In this case, intake of disulfiram
was accompanied by oral administration of Zn2+ gluconate
3x per day and the treatment regimen of reduced-dose
disulfiram with full dosing of Zn2+ gluconate was continued
for several years (similar to the case of acute childhood
leukemia described above). In our view, there were 3 substances
in this case used to treat the ocular melanoma that could
account for the success of the treatment: disulfiram, Zn2+
and gluconate, or a combination of these. The main substance
considered to have anti-cancer activity in this study was
disulfiram, while Zn2+ was intended to enhance its anti-
cancer activity. However, none of the published results from
clinical studies using disulfiram without heavy metal combined
with gluconate as the adjuvant therapy confirmed its anti-
cancer activity. In a recent study involving patients with
non-small cell lung carcinoma receiving cisplatin together
with disulfiram as adjuvant therapy (not accompanied by
heavy metal administration), no difference in the tumor
response rate was observed with chemotherapy plus or
minus disulfiram (44). Similarly, a study on cisplatin-sensitive
malignancies reported no significant difference in the time
to progression or median survival time between patients
treated with cisplatin and disulfiram, or cisplatin only (45).
No improvement of non-metastatic recurrent prostate cancer
was observed when different doses of disulfiram alone were
applied (46). Therefore, we raise the possibility that in the
case of tumor response with ocular melanoma liver metastasis,
gluconate should be considered as a potential mediator of anti-
cancer activity.
Ca2+ Gluconate
Gluconate has also been applied through injections to carry
Ca2+ to prevent neuropathy in patients receiving oxaloplatin
treatment. Oxaliplatin increases extracellular levels of oxalate
which chelates Ca2+. Decreased Ca2+ levels have been postulated
to induce prolonged activation of K+-independent voltage-gated
Na+ channels resulting in stress and mitochondrial damage of
nerve cells leading to neuropathy (47). To increase extracellular
Ca2+ levels and to prevent unwanted side effects during
oxaliplatin treatments for colorectal cancer, 1 g of Ca2+ gluconate
was injected before and after oxaliplatin infusion. Although there
is a general consensus that Ca2+ treatment does not affect the
efficiency of oxaliplatin treatment, there are conflicting results
regarding its use in decreasing neuropathy from no improvement
(48), decrease in acute sensory neuropathy (47), to a significant
reduction in neuropathy (49). While the first two studies were
performed on a small number of patients (∼20), the third
study included a larger cohort of 161 patients. Importantly, not
only a significantly better tolerance to oxaliplatin treatment was
observed in the patient group injected with Ca2+ gluconate, but
the anti-tumor response rate was increased from 35% (control)
to 45% in the Ca2+ gluconate pretreated group (49). Since the
studies were performed to test the effect of Ca2+ infusions on
neuropathy, the conclusions regarding any potential anti-tumor
effects of Ca2+ or gluconate can only be considered speculative at
this point.
GLUCONATE IN THE DIAGNOSIS OF
CANCER
Increased uptake of radioactive glucose has been used in positron
emission tomography (PET) analysis as an indicator of cancerous
lesions. A drawback of this technique is that glucose uptake is
not only associated with cancer, it is also typical of inflamed
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tissues. To overcome this problem several different labeled
substances have been studied as potential diagnostic markers.
Additionally, a search has been underway to find markers
that distinguish between metastatic and non-metastatic lesions
(50–53). These studies became particularly interesting with the
development of radiolabeling techniques that led to the synthesis
of new labels. One of them, presently used in many medical
diagnostic tests due to its relatively high radioactivity and a
short half-life, is technetium 99 (99mTc). While initial studies
indicated 99mTc-glucoheptonate as a promising substrate that
could help distinguish between benign and metastatic lesions
in the lung, more detailed studies showed that the specificity
was low. Therefore, other glucose derivatives such as gluconate
have been considered (54). The use of 99mTc-labeled gluconate
was efficient in the diagnosis of tumors of different origin,
including the detection of intracranial metastases (55). Another
trial revealed that labeled gluconate can be successfully used
to distinguish between benign and malignant lesions in the
lung, showing significantly better sensitivity and accuracy than
radiography (54). Similarly, promising results were obtained
when 99mTc-diethylenetriaminepentaacetic acid radionuclide-
based angiography was combined with 99mTc-gluconate renal
venography. This technique was used for the specific detection
of malignant lesions in kidney and bladder cancer (56), and
showed that the applied radiolabeled substances led to proper
localization of the lesions and accurate assessment of malignancy.
Additionally, it was observed that the use of 99mTc gluconate
significantly reduced background noise as compared to other
substances, and this was considered to be the major advantage
(55). Our recent publication (14) finally sheds light on why
gluconate binding to tumor is specific. We show that gluconate
binds irreversibly to the pmCiC expressed on cancer cells (14),
and the expression of pmCiC is high in metastatic lesions and
more advanced disease. Therefore, labeled gluconate has the
potential to distinguish between different tumor grades, although
this will require additional detailed studies.
Importantly, it has been observed that the concentration of
99mTc-gluconate reaches its highest level in the kidney 1–2 h
after injection (57). Moreover, there was no signal observed from
adjacent organs/tissues, indicating a lack of 99mTc-gluconate
uptake by healthy cells. The lack of 99mTc-gluconate uptake
by healthy organs and fast clearance through the kidney was
later confirmed (58). These features suggest that the potential
diagnostic use of gluconate would likely have few if any
side effects.
To summarize, early studies indicate that labeled gluconate is
useful in cancer diagnostics because of its ability to distinguish
between benign and metastatic lesions. Interestingly, until our
recent research findings (14), there was no explanation as to why
malignant cancers have an affinity for gluconate.
TREATMENT OPTIONS
Based on our own research and the available literature data
we suggest that gluconate should be studied in the context of
anti-cancer treatment. Electrophysiological experiments revealed
that gluconate blocking of citrate transport in cancer cells
is irreversible and the effect increases with every subsequent
application (14). Moreover, half-life of plasma membrane
proteins is relatively long and in the case of pmCiC it has been
established to be around 48h (14). Based on these data one
could speculate that smaller doses of gluconate taken frequently
should bemore effective than large bolus doses of gluconate given
e.g., IV. However, since nothing is known about oral gluconate
pharmacokinetics, dosing studies should be performed before
considering cancer treatment options. The possible effectiveness
of oral gluconate application would be consistent with the
successful treatment observed with the previously discussed
ocular melanoma (15) and acute lymphocytic leukemia (16)
cases where gluconate was given orally in small doses for
several years.
Blocking of the pmCiC could also have indirect positive
effects in cancer treatment. Indirect activity is possible since
blocking citrate uptake in cancer cells in vivo has been shown
to increase ROS synthesis (14). Indeed, increasing ROS synthesis
to promote cancer cell apoptosis is already part of the action
of several chemotherapeutics e.g., doxorubicin, daunorubicin or
epirubicin (59, 60). Therefore, pretreatment of cancer patients
receiving chemotherapy with gluconate should be explored
for beneficial effects by decreasing cancer cell resistance and
increasing efficiency of chemotherapy. For this purpose, single
large doses of gluconate given 24 and 48 h before administering
chemotherapy (49) should be considered.
With regard to potential side effects, there are currently no
reports of gluconate specifically exerting any adverse events
in patients. Side effects implicated when taking e.g., Zn2+
gluconate have been associated with increased Zn2+ absorption,
rather than gluconate action. Nonetheless, a safety assessment
will need to be made if gluconate does enter testing as an
anti-cancer agent.
CONCLUSIONS
In this review we have presented several independent clinical and
basic research studies in which gluconate was used incidentally
together with other substances to treat cancer. Indeed, gluconate
is considered to be physiologically neutral and therefore was
not administered in these cases as the drug substance. Since
putative anticancer agents like those described in this review tend
to show positive effects mainly when combined with gluconate,
an argument can be made for gluconate actually playing a
role in reported anticancer activities. These examples, together
with our latest research results showing that gluconate blocks
citrate transport into cancer cells and inhibits tumor growth in
mice, raises the intriguing hypothesis that gluconate use may
offer an interesting new diagnostic and treatment option in
cancer research.
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